Anbio Biotechnology director files initial Form 3

Anbio Biotechnology director XU CANY filed an initial ownership report on Form 3 as an insider of the company.

Rhea-AI Filing Summary

Anbio Biotechnology director XU CANY filed an initial ownership report on Form 3 as an insider of the company. The filing does not list any specific share holdings or recent transactions, serving only to formally register this individual’s insider status with the issuer.

Key Terms

Form 3, reporting person, ten percent owner

3 terms

Form 3 regulatory

"filed an initial ownership report on Form 3 as an insider"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"The reporting person is XU CANY, identified as a director"

ten percent owner regulatory

"is not identified as a ten percent owner of Anbio Biotechnology"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Anbio Biotechnology (NNNN) disclose in this Form 3 filing?

The Form 3 identifies XU CANY as a director of Anbio Biotechnology. It is an initial insider ownership report and does not list any specific transactions or detailed share positions.

Who is the reporting person in Anbio Biotechnology (NNNN) Form 3?

The reporting person is XU CANY, identified as a director of Anbio Biotechnology. This status means they are considered an insider for SEC reporting purposes under the company’s governance structure.

Does the Anbio Biotechnology (NNNN) Form 3 show any insider share transactions?

No, the Form 3 for Anbio Biotechnology shows zero buy, sell, acquire, or dispose transactions. The transaction summary counts are all zero, indicating only an initial ownership report without trading activity.

Are there derivative securities reported in the Anbio Biotechnology (NNNN) Form 3?

No derivative securities are reported for XU CANY in this Form 3. The derivative summary section is empty, meaning no options, warrants, or other derivative positions are listed in this filing.

Is XU CANY a ten percent owner of Anbio Biotechnology (NNNN) in this filing?

In this Form 3, XU CANY is not identified as a ten percent owner of Anbio Biotechnology. The field for ten percent owner status is marked as zero, indicating that threshold is not reported as met here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

XU CANY

(Last) (First) (Middle)

FRIEDRICH-EBERT-ANLAGE 35-37

(Street)

FRANKFURT AM MAIN 60327

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Anbio Biotechnology [ NNNN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ CANY XU	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)